0001214659-22-002681.txt : 20220214
0001214659-22-002681.hdr.sgml : 20220214
20220214165129
ACCESSION NUMBER: 0001214659-22-002681
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220211
FILED AS OF DATE: 20220214
DATE AS OF CHANGE: 20220214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FUCHS HENRY J
CENTRAL INDEX KEY: 0001197355
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35921
FILM NUMBER: 22633843
MAIL ADDRESS:
STREET 1: C/O BIOMARIN PHARMACEUTICAL INC.
STREET 2: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mirati Therapeutics, Inc.
CENTRAL INDEX KEY: 0001576263
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462693615
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3545 CRAY COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-332-3410
MAIL ADDRESS:
STREET 1: 3545 CRAY COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
marketforms-55390.xml
PRIMARY DOCUMENT
X0306
4
2022-02-11
0001576263
Mirati Therapeutics, Inc.
MRTX
0001197355
FUCHS HENRY J
C/O MIRATI THERAPEUTICS INC.
3545 CRAY COURT
SAN DIEGO
CA
92121
true
false
false
false
Common Stock
2022-02-11
4
M
false
6000
20.54
A
12021
D
Common Stock
2022-02-11
4
M
false
5000
20.54
A
17021
D
Common Stock
2022-02-11
4
S
false
2090
104.7646
D
14931
D
Common Stock
2022-02-11
4
S
false
8700
105.7963
D
6231
D
Common Stock
2022-02-11
4
S
false
210
106.3407
D
6021
D
Non Qualified Stock Option (right to buy)
20.54
2022-02-11
4
M
false
6000
0
D
2017-09-09
2024-09-08
Common Stock
6000
0
D
Non Qualified Stock Option (right to buy)
20.54
2022-02-11
4
M
false
5000
0
D
2014-09-09
2024-09-08
Common Stock
5000
0
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
This transaction was executed in multiple trades at prices ranging from $104.23 to $105.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $105.28 to $106.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $106.33 to $106.555. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
/s/ Vickie Reed, Attorney-in-Fact
2022-02-14